The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars
- 1 November 2019
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 76 (1) , 35-40
Abstract
A rapidly increasing use of biological drugs has led to substantial costs. Shift to biosimilars enables considerable reduction of these costs without jeopardizing the treatment of patients, but most countries have extensive possibilities of untapped cost-savings. The aim of this study was to describe the Danish quick and near-complete implementation of the two first TNF inhibitor biosimilars (infliximab and etanercept).Keywords
Funding Information
- P. Carl Petersens Fond (18071)
This publication has 6 references indexed in Scilit:
- Prescribing biosimilarsBMJ, 2018
- Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritisRMD Open, 2018
- Top drugs and companies by sales in 2017Nature Reviews Drug Discovery, 2018
- Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine careScandinavian Journal of Rheumatology, 2018
- A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registryAnnals of the Rheumatic Diseases, 2017
- Interchangeability of Biosimilars: A European PerspectiveBioDrugs, 2017